AzTrials
AzTrials

SchizophreniaPhase 3RISENCT03503318

Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia

A Phase 3 study testing TV-46000 in people with Schizophrenia, run by Teva Branded Pharmaceutical Products R&D, Inc. at 81 sites in 2 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of the study is to evaluate the efficacy, safety, and tolerability of different dose regimens of TV-46000 administered subcutaneously (SC) as compared to placebo during maintenance treatment in adult and adolescent participants with schizophrenia. Read more about this study

Who is it for?
Ages 13 to 65 years
Conditions the study is for
Schizophrenia
What is being tested?
TV-46000
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
544 participants
Where
81 sitesin 2 countries
Study dates
27 Apr 2018to 3 Dec 2020
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 13 to 65 years
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • The participant has a diagnosis of schizophrenia for >1 year and has had ≥1 episode of relapse in the last 24 months.
  • The participant has been responsive to an antipsychotic treatment (other than clozapine) in the past year based on discussions with family members or healthcare professionals.
  • The participant has a stable place of residence for the previous 3 months before screening, and changes in residence are not anticipated over the course of study participation.
  • The participant has no significant life events that could affect study outcomes expected throughout the period of study participation.
  • Women of childbearing potential and sexually-active female adolescents must agree not to try to become pregnant, and, unless they have exclusively same-sex partners, must agree to use a highly effective method of contraception, and agree to continue use of this method beginning 1 month before the first administration of study drugs and for the duration of the study and for 120 days after the last injection of study drug.
  • The participant, if adult or adolescent male, is surgically sterile, or, if capable of producing offspring, or has exclusively same-sex partners or is currently using an approved method of birth control and agrees to the continued use of this method for the duration of the study (and for 120 days after the last dose of study drug). Male participants with sex partners who are women of childbearing potential must use condoms even if surgically sterile
  • Additional criteria apply, please contact the investigator for more information

Who cannot join

  • The participant has a current clinically significant Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) diagnosis other than schizophrenia, including schizoaffective disorder, major depressive disorder, bipolar disorder, delirium, dementia, or amnestic or other cognitive disorders, or borderline, paranoid, histrionic, schizotypal, schizoid, or antisocial personality disorder.
  • The participant is currently on clozapine or received electroconvulsive therapy in the last 12 months.
  • The participant has a history of epilepsy or seizures, neuroleptic malignant syndrome, tardive dyskinesia, or other medical condition that would expose the participant to undue risk.
  • The participant has a positive serology for human immunodeficiency virus (HIV)-1, HIV-2, hepatitis B surface antigen, and/or hepatitis C.
  • The participant has current or history of known hypersensitivity to risperidone or any of the excipients of TV-46000 or the oral formulation of risperidone used in the stabilization phase.
  • The participant has a substance use disorder, including alcohol and benzodiazepines but excluding nicotine and caffeine.
Show all 11Show fewer
  • The participant has previously participated in a Teva-sponsored clinical study with TV-46000.
  • The participant is a pregnant or lactating female.
  • The participant has any disorder that may interfere with drug absorption, distribution, metabolism, or excretion (including gastrointestinal surgery).
  • The participant has used an investigational drug within 3 months prior to screening or has participated in a non-drug clinical trial within 30 days prior to screening.
  • Additional criteria apply, please contact the investigator for more information

Trial locations and contacts

81 sites in 2 countries.

81 sites in 2 countries

United States73 sites
  • Teva Investigational Site 14789

    Allentown, Pennsylvania, 18104

  • Teva Investigational Site 14811

    Anaheim, California, 92805

  • Teva Investigational Site 14824

    Atlanta, Georgia, 30331

  • Teva Investigational Site 14794

    Bellflower, California, 90706

  • Teva Investigational Site 14792

    Berlin, New Jersey, 08009

  • Teva Investigational Site 14772

    Cedarhurst, New York, 11516

  • Teva Investigational Site 14778

    Charleston, South Carolina, 29407

  • Teva Investigational Site 14765

    Chicago, Illinois, 60612

  • Teva Investigational Site 14829

    Chicago, Illinois, 60640

  • Teva Investigational Site 14763

    Cincinnati, Ohio, 45219

  • Teva Investigational Site 14776

    Colton, California, 92324

  • Teva Investigational Site 14834

    Columbus, Georgia, 31904

  • Teva Investigational Site 14768

    Coral Gables, Florida, 33134

  • Teva Investigational Site 14783

    Coral Gables, Florida, 33134

  • Teva Investigational Site 14767

    Costa Mesa, California, 92626

  • Teva Investigational Site 14802

    Costa Mesa, California, 92627

  • Teva Investigational Site 14773

    Culver City, California, 90230

  • Teva Investigational Site 14781

    Dallas, Texas, 75231

  • Teva Investigational Site 14766

    Dallas, Texas, 75243

  • Teva Investigational Site 14782

    Dayton, Ohio, 45417

  • Teva Investigational Site 14821

    Decatur, Georgia, 30030

  • Teva Investigational Site 14835

    Garden Grove, California, 92845

  • Teva Investigational Site 14764

    Glen Burnie, Maryland, 21061

  • Teva Investigational Site 14774

    Glendale, California, 91206

  • Teva Investigational Site 14836

    Hallandale, Florida, 33009

  • Teva Investigational Site 14787

    Hialeah, Florida, 33016

  • Teva Investigational Site 14814

    Hialeah, Florida, 33018

  • Teva Investigational Site 14805

    Hoffman Estates, Illinois, 60169

  • Teva Investigational Site 14801

    Houston, Texas, 77081

  • Teva Investigational Site 14807

    Irving, Texas, 75062

  • Teva Investigational Site 14817

    La Habra, California, 90631

  • Teva Investigational Site 14809

    Las Vegas, Nevada, 89102

  • Teva Investigational Site 14799

    Lauderhill, Florida, 33319

  • Teva Investigational Site 14771

    Lemon Grove, California, 91945

  • Teva Investigational Site 14769

    Little Rock, Arkansas, 72211

  • Teva Investigational Site 14823

    Long Beach, California, 90822

  • Teva Investigational Site 14770

    Marietta, Georgia, 30060

  • Teva Investigational Site 14832

    Miami, Florida, 33126

  • Teva Investigational Site 14816

    Montclair, California, 91763

  • Teva Investigational Site 14820

    New Bedford, Massachusetts, 02740

  • Teva Investigational Site 14804

    New York, New York, 10029

  • Teva Investigational Site 14800

    New York, New York, 10032

  • Teva Investigational Site 14784

    New York, New York, 10036

  • Teva Investigational Site 14833

    Norristown, Pennsylvania, 19403

  • Teva Investigational Site 14810

    North Miami, Florida, 33161

  • Teva Investigational Site 14803

    Norwalk, California, 90650

  • Teva Investigational Site 14786

    Oakland, California, 94607

  • Teva Investigational Site 14797

    Oceanside, California, 92054

  • Teva Investigational Site 14827

    Oceanside, California, 92056-4515

  • Teva Investigational Site 14822

    Oklahoma City, Oklahoma, 73112

  • Teva Investigational Site 14777

    Orange, California, 92868

  • Teva Investigational Site 14831

    Orange City, Florida, 32763

  • Teva Investigational Site 14806

    Orlando, Florida, 32810

  • Teva Investigational Site 14815

    Pico Rivera, California, 90660

  • Teva Investigational Site 14830

    Princeton, New Jersey, 08540

  • Teva Investigational Site 14812

    Riverside, California, 92506

  • Teva Investigational Site 14796

    Rogers, Arkansas, 72758

  • Teva Investigational Site 14798

    Saginaw, Michigan, 48603

  • Teva Investigational Site 14785

    San Bernardino, California, 92408

  • Teva Investigational Site 14818

    San Diego, California, 92103

  • Teva Investigational Site 14828

    San Diego, California, 92103

  • Teva Investigational Site 14819

    San Marcos, California, 92078

  • Teva Investigational Site 14779

    Santa Ana, California, 92705

  • Teva Investigational Site 14775

    Scranton, Pennsylvania, 18503

  • Teva Investigational Site 14825

    Shreveport, Louisiana, 71101

  • Teva Investigational Site 14791

    St Louis, Missouri, 63109

  • Teva Investigational Site 14813

    St Louis, Missouri, 63128

  • Teva Investigational Site 14826

    St Louis, Missouri, 63132

  • Teva Investigational Site 14790

    St Louis, Missouri, 63141

  • Teva Investigational Site 14780

    Staten Island, New York, 10312

  • Teva Investigational Site 14837

    Tampa, Florida, 33614

  • Teva Investigational Site 14793

    Thorndale, Pennsylvania, 19372

  • Teva Investigational Site 14788

    Torrance, California, 90502

Other trials in United States

Bulgaria8 sites
  • Teva Investigational Site 59148

    Burgas, 8000

  • Teva Investigational Site 59152

    Kazanlak, 6100

  • Teva Investigational Site 59151

    Lovech, 5500

  • Teva Investigational Site 59149

    Novi Iskar, 1282

  • Teva Investigational Site 59144

    Sofia, 1680

  • Teva Investigational Site 59154

    Varna, 9000

  • Teva Investigational Site 59150

    Varna, 9020

  • Teva Investigational Site 59146

    Vratsa, 3000

Other trials in Bulgaria

About this study

Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia

The purpose of the study is to evaluate the efficacy, safety, and tolerability of different dose regimens of TV-46000 administered subcutaneously (SC) as compared to placebo during maintenance treatment in adult and adolescent participants with schizophrenia. The study will include male and female participants, 13 to 65 years of age, who have a confirmed diagnosis of schizophrenia, are clinically stable, and are eligible for risperidone treatment

Conditions
Schizophrenia
Being tested
TV-46000, Placebo
Medical subject headings
Schizophrenia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • TV-46000Drug

    Also called Risperidone

    TV-46000 will be administered per dose and schedule specified in the arm.

  • PlaceboDrug

    Placebo matching to TV-46000 will be administered per schedule specified in the arm.

Study groups in NCT03503318
Study groupRoleWhat they receive
PlaceboPlacebo comparatorParticipants will receive an SC injection of placebo matching to TV-46000 at baseline and every 4 weeks (q4w) thereafter. Participants will continue treatment until they experience a relapse event; meet 1 or more of the study discontinuation or withdrawal criteria; or remain relapse-free during the double-blind phase until the study is terminated.
Receives: Drug: Placebo
TV-46000 q1mExperimentalParticipants will receive an SC injection of TV-46000 at baseline and q4w thereafter. The maximal dose for adult participants is comparable to an oral risperidone dose of 5 milligrams (mg)/day, and the maximal dose for adolescents is comparable to 4 mg/day. Participants will continue treatment until they experience a relapse event; meet 1 or more of the study discontinuation or withdrawal criteria; or remain relapse-free during the double-blind phase until the study is terminated.
Receives: Drug: TV-46000
TV-46000 q2mExperimentalParticipants will receive an SC injection of TV-46000 at baseline and every 8 weeks (q8w) thereafter, and a placebo SC injection 4 weeks after baseline and q8w thereafter. The maximal dose for adult participants is comparable to an oral risperidone dose of 5 mg/day, and the maximal dose for adolescents is comparable to 4 mg/day. Participants will continue treatment until they experience a relapse event; meet 1 or more of the study discontinuation or withdrawal criteria; or remain relapse-free during the double-blind phase until the study is terminated.
Receives: Drug: TV-46000; Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Time to Impending Relapse (Number of Participants With Impending Relapse) for Intent-to-treat [ITT] Analysis Set

    Relapse was defined as 1 or more of the following items: • Clinical Global Impression-Improvement (CGI-I) of ≥5, and - an increase of any of the 4 Positive and Negative Syndrome Scale (PANSS) items: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content, to a score of >4 with an absolute increase of ≥2 on specific item since randomization, or - an increase in any of the 4 individual PANSS items to a score of >4 and an absolute increase of ≥4 on combined score of 4 items since randomization; • hospitalization due to worsening of psychotic symptoms; • Clinical Global Impression-Severity of Suicidality (CGI-SS) of 4 (severely suicidal) or 5 (attempted suicide) on Part 1 and/or 6 (much worse) or 7 (very much worse) on Part 2; • violent behavior resulting in clinically significant self-injury, injury to another person, or property damage. Data is presented as distribution of relapsing participants (number of participants with impending relapse).

    Measured: From randomization up to 108 weeks

Secondary outcomes (16)
  1. Time to Impending Relapse (Number of Participants With Impending Relapse) for Extended ITT [eITT] Analysis Set

    Relapse was defined as 1 or more of the following items: • CGI-I of ≥5, and - an increase of any of the 4 PANSS items: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content, to a score of >4 with an absolute increase of ≥2 on specific item since randomization, or - an increase in any of the 4 individual PANSS items to a score of >4 and an absolute increase of ≥4 on combined score of 4 items since randomization; • hospitalization due to worsening of psychotic symptoms; • CGI-SS of 4 (severely suicidal) or 5 (attempted suicide) on Part 1 and/or 6 (much worse) or 7 (very much worse) on Part 2; • violent behavior resulting in clinically significant self-injury, injury to another person, or property damage. Data is presented as distribution of relapsing participants (adults and adolescents) (number of participants with impending relapse).

    Measured: From randomization up to 108 weeks

  2. Proportion of Participants With Impending Relapse

    Relapse was defined as 1 or more of the following items: • CGI-I of ≥5, and - an increase of any of the 4 PANSS items: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content, to a score of >4 with an absolute increase of ≥2 on specific item since randomization, or - an increase in any of the 4 individual PANSS items to a score of >4 and an absolute increase of ≥4 on combined score of 4 items since randomization; • hospitalization due to worsening of psychotic symptoms; • CGI-SS of 4 (severely suicidal) or 5 (attempted suicide) on Part 1 and/or 6 (much worse) or 7 (very much worse) on Part 2; • violent behavior resulting in clinically significant self-injury, injury to another person, or property damage. Impending relapse rate at Week 24 was estimated using the Kaplan-Meier product estimate.

    Measured: Week 24

  3. Number of Participants Who Maintain Stability at the Endpoint

    Stability is defined as meeting all of the following criteria for at least 4 consecutive weeks: outpatient status; PANSS total score ≤80; minimal presence of specific psychotic symptoms on the PANSS, as measured by a score of ≤4 on each of the following items: conceptual disorganization, suspiciousness, hallucinatory behavior, and unusual thought content; Clinical Global Impression of Severity (CGI-S) score ≤4 (moderately ill); and CGI-SS score ≤2 (mildly suicidal) on Part 1 and ≤5 (minimally worsened) on Part 2. The last valid participant assessment was used as the endpoint.

    Measured: At the endpoint (up to 108 weeks)

  4. Number of Participants Achieving Remission at the Endpoint

    The remission was achieved for participants who did not relapse during the study and for over a period of at least 6 months preceding the endpoint, maintained scores of = 3 on each of the 8 specific PANSS items: P1 (delusions), G9 (unusual thought content), P3 (hallucinatory behavior), P2 (conceptual disorganization), G5 (mannerisms/posturing), N1 (blunted affect), N4 (social withdrawal), and N6 (lack of spontaneity). The last valid participant assessment was used as the endpoint.

    Measured: At Endpoint (up to 108 weeks)

  5. Observed Rate of Impending Relapse (Number of Participants With Impending Relapse) at the Endpoint

    Relapse was defined as 1 or more of the following items: • CGI-I of ≥5, and - an increase of any of the 4 PANSS items: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content, to a score of >4 with an absolute increase of ≥2 on specific item since randomization, or - an increase in any of the 4 individual PANSS items to a score of >4 and an absolute increase of ≥4 on combined score of 4 items since randomization; • hospitalization due to worsening of psychotic symptoms; • CGI-SS of 4 (severely suicidal) or 5 (attempted suicide) on Part 1 and/or 6 (much worse) or 7 (very much worse) on Part 2; • violent behavior resulting in clinically significant self-injury, injury to another person, or property damage. Observed rate of impending relapse was calculated as the number of participants who relapsed by endpoint divided by the number of participants in each treatment group, using the last valid participant assessment as the endpoint.

    Measured: At the Endpoint (up to 108 weeks)

  6. Time to Impending Relapse (Number of Participants With Impending Relapse) in the Adolescent Participants

    Relapse was defined as 1 or more of the following items: • CGI-I of ≥5, and - an increase of any of the 4 PANSS items: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content, to a score of >4 with an absolute increase of ≥2 on specific item since randomization, or - an increase in any of the 4 individual PANSS items to a score of >4 and an absolute increase of ≥4 on combined score of 4 items since randomization; • hospitalization due to worsening of psychotic symptoms; • CGI-SS of 4 (severely suicidal) or 5 (attempted suicide) on Part 1 and/or 6 (much worse) or 7 (very much worse) on Part 2; • violent behavior resulting in clinically significant self-injury, injury to another person, or property damage. Data is presented as distribution of relapsing participants (adolescents) (number of participants with impending relapse).

    Measured: From randomization up to 108 weeks

  7. Change From Baseline in Drug Attitudes Inventory 10-item Version (DAI-10) Total Score at the Endpoint and End of Treatment

    The DAI-10 is a 10-item questionnaire to assess 1) subjective experience of drug and 2) attitudes and beliefs toward neuroleptics which may influence compliance in schizophrenia participants. The DAI-10 contains 6 items (1, 3, 4, 7, 9, and 10) that a participant who was fully adherent to the prescribed medication answered as "True" and 4 items (2, 5, 6, and 8) that a participant who was fully adherent to the prescribed medication answered as "False." A correct answer was scored +1 and an incorrect answer was scored -1. The total score was the sum of pluses and minuses, which ranged from -10 to 10 in increments of 2. A positive total score indicated a positive subjective response (compliant) and a negative total score indicated a negative subjective response (non-compliance). Higher scores denoted better compliance. The last valid participant assessment was used as the endpoint.

    Measured: Baseline, endpoint and end of treatment (up to Week 108)

  8. Change From Baseline in Schizophrenia Quality of Life Scale (SQLS) Total Score at the Endpoint and End of Treatment

    The SQLS comprises 33 items categorized in 2 domains: psychosocial feelings (20 items) and cognition and vitality (13 items). The items were scored on a 5-point scale (1 - never, 2 - rarely, 3 - sometimes, 4 - often, 5 - always). Individual domain and total scores were standardized by scoring algorithm to a 0 (best health status) to 100 (worst health status) scale, with higher scores indicating comparatively lower quality of life. The last valid participant assessment was used as the endpoint.

    Measured: Baseline, endpoint and end of treatment (up to Week 108)

  9. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were defined as AEs occurring after the first dose of the study drug until 120 days after the last dose of study drug. Serious AEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

    Measured: From randomization up to 120 days after last dose of study drug (up to Week 125)

  10. Change From Baseline in Total Abnormal Involuntary Movement Scale (AIMS) Score at the End of Treatment

    The AIMS is a 14-item scale that includes assessments of orofacial movements, extremity and truncal dyskinesia, examiner's judgment of global severity, subjective measures of awareness of movements and distress, and a yes/no assessment of problems concerning teeth and/or dentures. Total AIMS score is a sum of item 1 through 7. Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). Each item was rated on a 0 (no dyskinesia) to 4 (severe dyskinesia) scale. Total AIMS score for Items 1-7 ranged from 0 to 28; with higher scores indicating greater severity of the condition.

    Measured: Baseline, end of treatment (up to 108 weeks)

  11. Change From Baseline in Simpson-Angus Scale (SAS) Mean Score at the End of Treatment

    The SAS is a 10-item instrument for the assessment of neuroleptic-induced parkinsonism. The items on the scale include measurements of hypokinesia, rigidity, glabellar reflex, tremor, and salivation. Each item was rated on a 5-point scale (0 [None/Normal] to 4 [Extreme/Severe]). The mean score was calculated by adding the individual item scores and dividing by 10. The total mean score ranged from 0-4, with a higher score indicating greater severity of symptoms.

    Measured: Baseline, end of treatment (up to 108 weeks)

  12. Change From Baseline in Total Barnes Akathisia Rating Scale (BARS) Score at the End of Treatment

    The BARS is an instrument that assesses the severity of drug-induced akathisia. The BARS includes 3 items for rating objective restless movements, subjective restlessness, and any subjective distress associated with akathisia that were scored on a 4-point scale of 0 (normal/no distress) to 3 (constant restlessness/severe distress). Total score was the sum of scores of each item and ranged from 0-9, with higher scores indicating greater severity of akathisia.

    Measured: Baseline, end of treatment (up to 108 weeks)

  13. Number of Participants Reporting Suicidal Behavior and Suicidal Ideation Using Columbia-Suicide Severity Rating Scale (C-SSRS) at Baseline and Post-Baseline

    The C-SSRS is a semi-structured interview that captures the occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal behavior was defined as a "yes" answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal ideation was defined as a "yes" answer to any one of 5 suicidal ideation questions: wish to be dead, and 4 different categories of active suicidal ideation.

    Measured: Baseline, post-baseline (up to 108 weeks)

  14. Change From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) Score at the End of Treatment

    The CDSS is specifically designed to assess the level of depression separate from the positive, negative, and EPS in schizophrenia. This clinician-administered instrument consists of 9 items, each rated on a 4-point scale from 0 (absent) to 3 (severe) that were added together to form the total CDSS depression score of the participant. The total score ranged from 0-27, with higher scores indicating greater severity of the condition.

    Measured: Baseline, end of treatment (up to 108 weeks)

  15. Change From Baseline in Clinical Global Impression-Severity of Suicidality (CGI-SS) Score at the End of Treatment

    The CGI-SS scale provides an overall clinician-rated assessment of the risk of suicidality. The CGI-SS consists of a 5-point scale in Part 1 (the most severe level of suicidality experience) ranging from 1 (not at all suicidal) to 5 (attempted suicide) and a 7-point scale in Part 2 (change in participant suicidality) ranging from 1 (very much improved) to 7 (very much worse).

    Measured: Baseline, end of treatment (up to 108 weeks)

  16. Plasma Concentration of Risperidone, 9-OH-risperidone, and Total Active Moiety (Sum of Risperidone and 9-OH-risperidone)

    Measured: 1 hour prior to dosing at Baseline (Day 1) and at the end of treatment visit (up to 108 weeks)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Apr 2018
  2. Study start27 Apr 2018
  3. Primary completion30 Sep 2020
  4. Study completion3 Dec 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
544 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03503318
Sponsor's protocol ID
TV46000-CNS-30072
Other IDs
2018-001619-65, 2018
Acronym
RISE
Status last verified
Feb 2023
First submitted
9 Apr 2018
Last updated
10 Mar 2023
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: Qualified researchers may request access to patient level data and related study documents including the study protocol and the statistical analysis plan. Requests will be reviewed for scientific merit, product approval status, and conflicts of interest. Patient level data will be de-identified and study documents will be redacted to protect the privacy of trial participants and to protect commercially confidential information. Please email USMedInfo@tevapharm.com to make your request.)

Publications

  • Kane JM, Tohami O, Franzenburg KR, Suett M, Sharon N, Merenlender-Wagner A, Eshet R, Harary E, Correll CU. Effects of Long-Term Treatment with TV-46000 on Symptom Improvement Over Time in Stabilized Patients with Schizophrenia. CNS Drugs. 2026 Feb;40(2):247-267. doi: 10.1007/s40263-025-01240-1. Epub 2025 Nov 21.

    PubMed 41272239
  • Correll CU, Knebel H, Harary E, Eshet R, Tohami O, Suett M, Sharon N, Franzenburg KR, Kane JM. Safety Outcomes with the Long-Acting Subcutaneous Antipsychotic TV-46000 in Schizophrenia: A Post Hoc Analysis of Behavioral, Neuromotor, Endocrine, and Cardiometabolic Outcomes from Two Phase 3 Studies. CNS Drugs. 2025 Nov;39(11):1139-1156. doi: 10.1007/s40263-025-01197-1. Epub 2025 Jul 29.

    PubMed 40730715
  • Kane JM, Harary E, Eshet R, Tohami O, Weiser M, Leucht S, Merenlender-Wagner A, Sharon N, Davis GL 3rd, Suett M, Franzenburg KR, Correll CU. Efficacy and safety of TV-46000, a long-acting, subcutaneous, injectable formulation of risperidone, for schizophrenia: a randomised clinical trial in the USA and Bulgaria. Lancet Psychiatry. 2023 Dec;10(12):934-943. doi: 10.1016/S2215-0366(23)00288-2. Epub 2023 Nov 2.

    PubMed 37924833

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing TV-46000 in people with Schizophrenia, run by Teva Branded Pharmaceutical Products R&D, Inc. at 81 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 10 Mar 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 81 sites in United States, Bulgaria. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 9 Dec 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Time to Impending Relapse (Number of Participants With Impending Relapse) for Intent-to-treat [ITT] Analysis Set (time frame: From randomization up to 108 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03503318, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Mar 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in